This webpage provides answers to frequently asked questions from physicians about buprenorphine and the Drug Addiction Treatment Act of 2000 (DATA 2000). In addition to having a physician section, there is a section for patients and pharmacists.
This handout discusses how a prescribing physician may prepare for a visit from the DEA. Such visits are required by law for physicians prescribing buprenorphine, and involve things such as prescription and dispensing records, and adherence to prescribing limits on number of patients.
This patient consent form (in Word®) explains buprenorphine treatment and warns about the adverse effects of mixing buprenorphine with other medications. The section at the bottom is for the patient and a witness to sign and date, indicating that the patient understands and wishes to receive treatment.
The California Society of Addiction Medicine (CSAM) website provides information and materials for buprenorphine treatment providers, including screening tools and sample consent and patient agreement forms, and provides links to other helpful resources.
PCSS-MAT is a free mentoring service funded by SAMHSA and coordinated by ASAM. The PCSS-MAT can match you with a physician mentor from your local area with whom you can discuss practice and treatment issues with him/her. NOTE: was previously known as PCSS-B for buprenorphine
A member of The Clinical Tools, Inc (CTI) Addiction Training Group: SBIRT Training | Opioid Risk Reduction | Buprenorphine Training
Clinical Tools, Inc. is accredited by the ACCME to provide continuing medical education for physicians. Interactive training is delivered by the CTI Learning Ecosystem and our FAOS DLearning Drupal modules and requires IE 7/ higher, Firefox, Chrome or Safari.
Unless otherwise noted, individuals pictured are models and are used for illustrative purposes only.